CVS Health (NYSE:CVS) Releases Earnings Results, Beats Expectations By $0.72 EPS

CVS Health (NYSE:CVS) announced its earnings results on Wednesday. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.86 by $0.72, FiscalAI reports. The company had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.CVS Health’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.81 earnings per share. CVS Health updated its FY 2026 guidance to 7.900-8.100 EPS.

Here are the key takeaways from CVS Health’s conference call:

• CVS raised its 2026 outlook after a strong quarter, increasing adjusted EPS guidance by $0.60 to $7.90–$8.10 and raising operating cash-flow expectations to at least $11.5 billion.
• Second-quarter performance was broad-based: revenue rose more than 7% to over $106 billion, adjusted operating income increased 35% to approximately $5.2 billion, and adjusted EPS grew over 40% to $2.58. All operating segments reported year-over-year earnings growth.
• Aetna’s margin recovery is progressing faster than expected, with more than $2 billion of year-to-date adjusted operating-income improvement; management cited disciplined pricing, medical-cost management, and favorable Medicare performance.
• Management sees growing opportunities in GLP-1s through formulary management, cash-pay offerings, MinuteClinic weight-management visits, and manufacturer partnerships with Lilly and Novo. The company plans to reduce the virtual weight-management visit price to $29 and expand same-day pharmacy access.
• CVS expects 2027 headwinds from continued pressure in its 340B business and lower Caremark membership, partly due to more selective contracting and health-plan product exits. Management said these pressures should be offset over time by specialty pharmacy growth, generic savings, and broader enterprise momentum.

CVS Health Stock Down 4.1%

Shares of NYSE:CVS traded down $4.28 during trading on Wednesday, reaching $100.14. 12,758,428 shares of the company traded hands, compared to its average volume of 8,420,878. The firm has a fifty day simple moving average of $101.96 and a 200 day simple moving average of $87.43. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. CVS Health has a 1-year low of $62.52 and a 1-year high of $110.68. The firm has a market cap of $127.77 billion, a P/E ratio of 44.06, a price-to-earnings-growth ratio of 1.03 and a beta of 0.61.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd were given a $0.665 dividend. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.7%. CVS Health’s dividend payout ratio is presently 117.18%.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS reported adjusted earnings of $2.58 per share, well above the roughly $1.86-$1.87 consensus, while revenue rose 7.3% year over year to $106.1 billion, also exceeding estimates. CVS raises guidance as it posts nearly $3B in profit, $106B in revenue for Q2
• Positive Sentiment: Improved medical-cost trends at Aetna, a more profitable pharmacy-drug mix and bonus payments tied to highly rated government health plans helped drive the nearly $2.9 billion quarterly profit. All three major segments—insurance, pharmacy and health services—beat revenue expectations. CVS blows past estimates, hikes guidance as insurance unit continues to improve
• Positive Sentiment: CVS raised its 2026 adjusted EPS outlook to $7.90-$8.10 from $7.30-$7.50, increased GAAP EPS guidance to $6.84-$7.04, and lifted operating-cash-flow guidance to at least $11.5 billion from $9.5 billion. Year-to-date operating cash flow was $10.6 billion. CVS Health Corporation reports strong second quarter 2026 results and raises guidance
• Positive Sentiment: The company launched an expanded GLP-1 weight-management offering and a collaboration with Eli Lilly, including access to Zepbound through CVS Pharmacy, lower-cost MinuteClinic digital visits and same-day prescription pickup. The initiative could support growth in pharmacy, care delivery and consumer health services. CVS enhances direct-to-consumer weight management offerings

Insiders Place Their Bets

In related news, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the completion of the sale, the director directly owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. This trade represents a 24.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares in the company, valued at approximately $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,441,551 shares of company stock worth $323,703,977 over the last ninety days. 0.85% of the stock is currently owned by company insiders.

Institutional Trading of CVS Health

A number of institutional investors have recently added to or reduced their stakes in CVS. Wellington Management Group LLP raised its holdings in shares of CVS Health by 193.2% during the 4th quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator’s stock valued at $1,473,270,000 after purchasing an additional 12,233,675 shares in the last quarter. Amundi increased its position in CVS Health by 95.3% during the third quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock worth $572,665,000 after buying an additional 3,637,943 shares during the last quarter. Morgan Stanley raised its holdings in CVS Health by 6.3% during the fourth quarter. Morgan Stanley now owns 20,373,774 shares of the pharmacy operator’s stock valued at $1,616,863,000 after buying an additional 1,211,631 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of CVS Health by 148.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,467,170 shares of the pharmacy operator’s stock worth $110,610,000 after buying an additional 876,443 shares during the last quarter. Finally, Maple Rock Capital Partners Inc. acquired a new stake in shares of CVS Health in the fourth quarter worth about $64,790,000. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have commented on CVS. Robert W. Baird upped their price objective on shares of CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a research note on Wednesday, April 15th. Wells Fargo & Company boosted their price target on shares of CVS Health from $103.00 to $123.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Truist Financial upped their price target on shares of CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Sanford C. Bernstein lifted their price objective on shares of CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 12th. Finally, TD Cowen boosted their target price on shares of CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Twenty-one investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $105.67.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.